Publications by authors named "Charles Craig"

Claim this Profile
C
Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction.
John Steytler, Charles Craig, Elna van der Ryst, Ben Van Baelen, Jeremy Nuttall

Clin Infect Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials-The Ring Study and DREAM.
John Steytler, Elna van der Ryst, Charles Craig, Ben Van Baelen, Jeremy Nuttall

Clin Infect Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Annalene Nel, Neliëtte van Niekerk, Ben Van Baelen, Mariëtte Malherbe, Winél Mans, Charles Craig

Lancet HIV· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.
Becky Jubb, Marilyn Lewis, Lynn McFadyen, Paul Simpson, Julie Mori, Charles Craig

Antivir Chem Chemother· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
Marilyn Lewis, Julie Mori, Jonathan Toma, Mike Mosley, Wei Huang, Charles Craig

PLoS One· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.
Jayvant Heera, Srinivas R Valluri, Charles Craig, Annie Fang, Neal Thomas

New Microbiol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.
Carlo Giaquinto, Muthuhadini Patience Mawela, Kulkanya Chokephaibulkit, Marinella Della Negra, Ismail Haroon Mitha, Charles Craig

Pediatr Infect Dis J· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The maraviroc expanded access program - safety and efficacy data from an open-label study.
Adriano Lazzarin, Jacques Reynes, Jean-Michel Molina, Srinivas Valluri, Geoffrey Mukwaya, Charles Craig

HIV Clin Trials· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.
Hans-Jürgen Stellbrink, Eric Le Fevre, Andrew Carr, Michael S Saag, Geoffrey Mukwaya, Charles Craig

AIDS· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.
Jayvant Heera, Srinivas Valluri, Charles Craig, Annie Fang, Neal Thomas

J Int AIDS Soc· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Xiaowei Jiang, Felix Feyertag, Conor J Meehan, Grace P McCormack, Simon A Travers, Charles Craig

J Virol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.
Edwin DeJesus, Gerd Fätkenheuer, Catherine Orrell, Cunshan Wang, James Jones, Charles Craig

HIV Clin Trials· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.
Sonya J Snedecor, Lavanya Sudharshan, Katherine Nedrow, Abhijeet Bhanegaonkar, Kit N Simpson, Charles Craig

AIDS Res Hum Retroviruses· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Anthony Mills, Donna Mildvan, Daniel Podzamczer, Gerd Fätkenheuer, Manuel Leal, Charles Craig

J Acquir Immune Defic Syndr· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
Pietro Vernazza, Cunshan Wang, Anton Pozniak, Elizabeth Weil, Piotr Pulik, Charles Craig

J Acquir Immune Defic Syndr· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.
Simon Portsmouth, Srinivas Rao Valluri, Martin Däumer, Bernhard Thiele, Hernan Valdez, Charles Craig

Antiviral Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
Philip J F Troke, Marilyn Lewis, Paul Simpson, Katrina Gore, Jennifer Hammond, Charles Craig

Antimicrob Agents Chemother· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
Juan Sierra-Madero, Giovanni Di Perri, Robin Wood, Michael Saag, Ian Frank, Charles Craig

HIV Clin Trials· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Jean-Michel Molina, Mounir Ait-Khaled, Roberto Rinaldi, Giovanni Penco, Jean-Guy Baril, Charles Craig

J Antimicrob Chemother· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
Jeffrey A Johnson, Jin-Fen Li, Xierong Wei, Jonathan Lipscomb, David Irlbeck, Charles Craig

PLoS Med· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Richard Hazen, Robert Harvey, Robert Ferris, Charles Craig, Phillip Yates

Antimicrob Agents Chemother· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Diane Descamps, Mounir Ait-Khaled, Charles Craig, Séverine Delarue, Florence Damond

Antivir Ther· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).
Anthony Lamarca, Nathan Clumeck, Andreas Plettenberg, Pere Domingo, Kaisong Fu, Charles Craig

J Acquir Immune Defic Syndr· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.
Graeme J Moyle, Edwin DeJesus, Pedro Cahn, Steve A Castillo, Henry Zhao, Charles Craig

J Acquir Immune Defic Syndr· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experimental investigations regarding the etiology of dengue fever. 1907.
P M Ashburn, Charles F Craig,

J Infect Dis· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis